Septerna, Inc. (NASDAQ:SEPN) Stock Has Average Target Price of $53.67

Shares of Septerna, Inc. (NASDAQ:SEPN) have been given an average rating of “Moderate Buy” by the eleven ratings firms that are currently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating, eight have issued a buy rating and one has issued a strong buy rating on the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $53.67.

Several brokerages have issued reports on SEPN. Guggenheim upped their price target on shares of Septerna from $45.00 to $51.00 and gave the company a “buy” rating in a report on Tuesday, August 11th. Stifel Nicolaus set a $49.00 price objective on Septerna in a research report on Tuesday, August 11th. JonesTrading lifted their price objective on Septerna from $43.00 to $62.00 and gave the stock a “buy” rating in a research report on Thursday, August 13th. Wells Fargo & Company upped their target price on Septerna from $50.00 to $61.00 and gave the company an “overweight” rating in a research note on Wednesday. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Septerna in a report on Thursday, October 15th.

Insider Buying and Selling at Septerna

In other news, SVP Daniel Long sold 3,333 shares of the company’s stock in a transaction on Tuesday, September 1st. The stock was sold at an average price of $37.83, for a total value of $126,087.39. Following the sale, the senior vice president directly owned 96,412 shares in the company, valued at $3,647,265.96. This represents a 3.34% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Elizabeth Bhatt sold 4,000 shares of the stock in a transaction on Thursday, October 15th. The shares were sold at an average price of $37.41, for a total value of $149,640.00. Following the sale, the chief operating officer directly owned 174,209 shares in the company, valued at approximately $6,517,158.69. The trade was a 2.24% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 32,333 shares of company stock worth $1,375,727 over the last 90 days. Company insiders own 5.80% of the company’s stock.

Institutional Investors Weigh In On Septerna

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Renaissance Technologies LLC acquired a new position in Septerna in the first quarter valued at $906,000. TRV GP V LLC acquired a new stake in Septerna during the second quarter worth about $208,160,143. VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new stake in Septerna during the second quarter worth about $445,000. First Light Asset Management LLC raised its holdings in shares of Septerna by 31.4% in the 2nd quarter. First Light Asset Management LLC now owns 963,260 shares of the company’s stock worth $32,260,000 after purchasing an additional 230,400 shares during the period. Finally, TRV GP VI LLC purchased a new position in shares of Septerna in the 2nd quarter worth about $141,048,460.

Septerna Stock Performance

Shares of SEPN stock opened at $47.88 on Thursday. The stock has a fifty day moving average price of $39.21 and a 200 day moving average price of $32.38. The stock has a market cap of $2.24 billion, a PE ratio of -88.67 and a beta of 2.20. Septerna has a 1 year low of $17.55 and a 1 year high of $51.10.

Septerna (NASDAQ:SEPN) last posted its earnings results on Monday, August 10th. The company reported ($0.29) earnings per share for the quarter, beating the consensus estimate of ($0.43) by $0.14. The company had revenue of $26.75 million for the quarter, compared to analyst estimates of $19.22 million. Septerna had a negative return on equity of 9.57% and a negative net margin of 24.51%. As a group, equities research analysts predict that Septerna will post -1.41 earnings per share for the current year.

About Septerna

Septerna, Inc is a clinical-stage biotechnology company focused on discovering and developing oral small-molecule medicines that target G protein-coupled receptors (GPCRs). GPCRs are a large class of cell-surface proteins involved in a wide range of biological processes and represent an important source of potential drug targets.

The company’s research is powered by its Native State platform, which is designed to study GPCRs in their natural biological configuration and support the discovery of selective small-molecule compounds.